Evidence map›Paper›PMID 23166616›Full record

ArticlePloS one2012

Study of association of CD40-CD154 gene polymorphisms with disease susceptibility and cardiovascular risk in Spanish rheumatoid arthritis patients.

Mercedes García-Bermúdez, Carlos González-Juanatey, Raquel López-Mejías, María Teruel, Alfonso Corrales, José A Miranda-Filloy, Santos Castañeda, Alejandro Balsa, Benjamín Fernández-Gutierrez, Isidoro González-Álvaro and 5 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. IgA Vasculitis: Influence ofJournal of clinical medicine · 2022
    Article
  4. Atherosclerosis in Rheumatoid Arthritis: Promoters and Opponents.Clinical reviews in allergy & immunology · 2020
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. CD40L and Its Receptors in Atherothrombosis-An Update.Frontiers in cardiovascular medicine · 2017
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Cardiovascular involvement in autoimmune diseases.BioMed research international · 2014
    Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 1 country.

Mercedes García-BermúdezInstituto de Parasitología y Biomedicina López-Neyra, IPBLN-C.S.I.C., Granada, Spain.
Carlos González-Juanatey
Raquel López-Mejías
María Teruel
Alfonso Corrales
José A Miranda-Filloy
Santos Castañeda
Alejandro Balsa
Benjamín Fernández-Gutierrez
Isidoro González-Álvaro
Carmen Gómez-Vaquero
Ricardo Blanco
Javier Llorca
Javier Martín
Miguel A González-Gay
Fundación Marques de Valdecilla · ESInstituto de Parasitología y Biomedicina "López - Neyra" · ESHospital Universitario de La Princesa · ESHospital Xeral Calde · ESHospital Clínico San Carlos · ESHospital Universitario La Paz · ESInstitut d'Investigació Biomédica de Bellvitge · ESUniversidad de Cantabria · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveRheumatoid arthritis (RA) is a chronic inflammatory disease associated with increased cardiovascular (CV) mortality. Since CD40-CD154 binding has direct consequences on inflammation process initiation, we aimed to replicate previous findings related to disease susceptibility in Spanish RA population. Furthermore, as the major complication in RA disease patients is the development of CV events due to accelerated atherosclerosis, and elevated levels of CD40L/CD154 are present in patients with acute myocardial infarction, we assessed the potential association of CD40 and CD154/CD40L gene variants with CV risk in Spanish RA patients.

methodsOne thousand five hundred and seventy-five patients fulfilling the 1987 ACR classification criteria for RA and 1600 matched controls were genotyped for the CD40 rs1883832, rs4810485 and rs1535045 and CD154 rs3092952 and rs3092920 gene polymorphisms, using predesigned TaqMan single nucleotide polymorphism genotyping assays. Afterwards, we investigated the influence of CD40-CD154 gene variants in the development of CV events. Also, in a subgroup of 273 patients without history of CV events, we assessed the influence of these polymorphisms in the risk of subclinical atherosclerosis determined by carotid ultrasonography.

resultsNominally significant differences in the allele frequencies for the rs1883832 CD40 gene polymorphism between RA patients and controls were found (p=0.038). Although we did not observe a significant association of CD40-CD154 gene variants with the development of CV events, an ANCOVA model adjusted for sex, age at the time of the ultrasonography assessment, follow-up time, traditional CV risk factors and anti-cyclic citrullinated peptide antibodies disclosed a significant association (p=0.0047) between CD40 rs1535045 polymorphism and carotid intima media thickness, a surrogate marker of atherosclerosis.

conclusionData from our pilot study indicate a potential association of rs1883832 CD40 gene polymorphism with susceptibility to RA. Also, the CD40 rs1535045 gene variant may influence development of subclinical atherosclerosis in RA patients.

Indexed as

Analysis of VarianceArthritis, RheumatoidCardiovascular DiseasesCarotid Intima-Media ThicknessCD40 AntigensCD40 LigandGene FrequencyGenetic Association StudiesGenetic Predisposition to DiseaseHumansPolymorphism, Single NucleotideSpainCD40 AntigensCD40 Ligand

Identifiers

PMID23166616
PMCPMC3499567
OpenAlexW2023502027

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.